Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7798 in Moderate to Severe Crohn's Disease
NCT06450197Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 2 trial of azd7798 in Crohn's disease, sponsored by AstraZeneca. Started Aug 2024; status: active, not recruiting.
02
Drugs
azd7798
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06450197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450197.